Based on current clinical evidence, the rough ordering from largest to smallest weight-loss effect is: Tirzepatide highest average weight loss Semaglutide significant weight loss Tesamorelin moderate weight loss, primarily through visceral fat reduction AOD-9604 primarily body composition effects MOTS-c primarily metabolic and energy effects rather than pure weight reduction AOD-9604 and MOTS-c are generally not considered replacements for GLP-1 medications in patients seeking substantial weight reduction
B12 is essential in the health of our blood cells, nerves and brain, DNA/RNA repair, and liver metabolism
Trust the timeline and storage conditions more than visual appearance
The Phase 2 trial results Published in the New England Journal of Medicine, the Phase 2 trial showed that participants receiving the highest dose of retatrutide (12mg weekly) achieved a mean weight reduction of 24.2% at 48 weeks
High performance liquid chromatography for detailed analysis of peptide composition and quality
Refrigerate at 28 C in the sealed vial, upright, away from light, and away from freeze-thaw cycles